Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Magnetically-enhanced cell therapy and Philips' cancer biomarkers for personalised treatment

This article was originally published in Clinica

Executive Summary

As of this edition, Clinica’s Patent Watch has changed its focus to medtech areas which are witnessing fast growth. These include regenerative medicine, drug delivery and emerging areas within personalised medicine such as molecular diagnostics. New patent applications published in May and June 2011 include tissue engineered vascular and orthopaedic grafts, drug-eluting gastrointestinal stents, ultrasound-triggered drug delivery, and diagnostic markers for cancer progression and prognosis.

You may also be interested in...



ResMed Jumps On Board As Nyxoah Raises €25m For Neurostim Apnea Device

The proceeds from the investment will enable Nyxoah to prepare for the IDE pivotal trial of the Genio system in the US, and accelerate market access and commercialization activities in Europe, Australia and New Zealand.

Editor's Note: Tell Us Your Views In Our Customer Survey

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you would like to see in the format of the content or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Knees Boost Zimmer Biomet; Turnaround Continues, But FDA Woes Linger

Zimmer Biomet reported Q4 results that reflected solid progress in the company’s turnaround efforts, with knees leading the charge. But the company is making slower-than-expected progress resolving FDA warning letter issues and faces a new bribery lawsuit in Mexico.

Topics

UsernamePublicRestriction

Register

MT097620

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel